Poly(ADP-ribose) polymerase (PARP) and PARP inhibitors
- Lookup NU author(s)
- Professor Nicola Curtin
|
|
|
|
| Author(s) | | Curtin NJ |
| Publication type | | Article |
| Journal | | Drug Discovery Today: Disease Models |
| Year | | 2012 |
| Volume | | 9 |
| Issue | | 2 |
| Pages | | e51-e58 |
| ISSN (electronic) | | 1740-6757 |
|
|
|
| Full text for this publication is not currently held within this repository. Alternative links are provided below where available. |
|
|
|
|
| PARP-1 protects cells from endogenous and therapeutically inflicted DNA damage. PARP inhibitors have been under development since 1980 and first entered clinical trial in 2003. They are an exciting new class of drugs that have the potential to increase the efficacy of anticancer DNA damaging agents and to selectively target cells that have defects in other DNA repair pathways. There are now nine PARP inhibitors undergoing clinical evaluation |
|
|
|
| Publisher | | Elsevier Ltd |
| URL | | http://dx.doi.org/10.1016/j.ddmod.2012.01.004 |
| DOI | | 10.1016/j.ddmod.2012.01.004 |
|
|
Actions | |   |
